STACKD Research is educational—not medical advice. Disclaimer

STACKDResearchSign up

STACKD summary

Limited human data

GH-axis secretagogues: CJC-1295 and ipamorelin

What's actually measured (GH pulses) vs. what's usually claimed (physique).

Muscle / GH axisRecoverySleep / recovery adjunct

Plain-language summary

CJC-1295 and ipamorelin are the classic “GH-axis” pairing. CJC-1295 nudges the pituitary to release growth hormone via the GHRH pathway; ipamorelin does it through a different door (the ghrelin receptor). Human pharmacology studies do show these compounds can raise GH and IGF-1. What's much weaker is the leap from “raises a hormone” to “builds muscle, improves recovery, or fixes sleep” in healthy lifters.

What was studied

Human pharmacokinetic / pharmacodynamic studies measuring GH and IGF-1 responses. CJC-1295 has data on sustained GH/IGF-1 elevation; ipamorelin has early human characterization emphasizing selective GH release with comparatively limited effects on cortisol/ACTH.

Key takeaways

  • The measured endpoint is hormone release, not body composition—that distinction is the whole ballgame.
  • Ipamorelin's selling point in the literature is selectivity (less impact on cortisol/prolactin than some older GHRPs).
  • CJC-1295 exists in DAC and non-DAC (Mod GRF 1-29) forms with very different durations—product labels online are frequently imprecise.
  • Evidence tier is “limited human”: real human pharmacology, but not outcome trials in athletes.

Multi-study synthesis

Taken together, these studies establish that CJC-1295 and ipamorelin can do what they say at the hormonal level—move GH and IGF-1. They do not establish the downstream fitness outcomes people actually care about. Reading the pair together mostly highlights how much of the popular narrative lives in the gap between a measurable hormone bump and an unproven real-world result.

Limitations & what we don't know

  • Physique, strength, and recovery benefits in healthy people are largely extrapolated from GH physiology, not demonstrated in trials.
  • Raising GH/IGF-1 carries theoretical risks (fluid retention, insulin resistance, IGF-1 elevation).
  • Compound identity (DAC vs non-DAC) is often unclear in gray-market products.
  • Sleep and recovery claims are mostly anecdotal.

Sources

Primary citations behind this summary. External links are provided for verification—read them yourself before drawing conclusions.

  1. 1.
    Prolonged stimulation of GH and IGF-I secretion by CJC-1295

    2006 · human

    Sustained GH and IGF-I elevation in humans.

  2. 2.
    Ipamorelin, the first selective growth hormone secretagogue

    1998 · human

    Early characterization of selective GH release.